3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1/2
8
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Carcinoma, Renal Cell
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
2
cemiplimab
1
avelumab
1
atezolizumab
1
Saline Solution
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Merkel Cell
×
avelumab
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled